GSK has received approval from the US Food and Drug Administration (FDA) for Blenrep (belantamab mafodotin-blmf) in ...
GSK has boosted its pipeline of antibody-drug conjugates for cancer, licensing a prostate cancer candidate from Syndivia in a ...
GSK’s Blenrep receives US FDA approval to treat relapsed/refractory multiple myeloma: London, UK Saturday, October 25, 2025, 11:00 Hrs [IST] GSK plc announced the US Food and Dr ...
The Food and Drug Administration (FDA) has approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory ...
The FDA has approved belantamabmafodotin (Blenrep) in combination with bortezomib (Velcade) and dexamethasone (BVd)for the ...
Investor's Business Daily on MSN
GSK Crumbles As Blood Cancer Comeback Falls Unexpectedly Short
GSK stock crumbled Friday after the FDA granted its blood cancer treatment, Blenrep, a narrower-than-expected approval.
GSK announced FDA’s approval of Blenrep in combination with bortezomib and dexamethasone (BVd) for the treatment of adults diagnosed with relapsed or refractory multiple myeloma who received a minimum ...
The US Food and Drug Administration (FDA) has approved UK pharma major GSK’s Blenrep belantamab mafodotin-blmf) in ...
The FDA approved of Blenrep in combination with bortezomib and dexamethasone (BVd) for adults with relapsed or refractory multiple myeloma who have received at least two prior therapies.
CURE spoke with Dr. Surbhi Sidana about the recently approved antibody-drug conjugate Blenrep for multiple myeloma.
The blue-chip index FTSE 100 rose 0.06% and the British GBP/USD fell 0.2% against the dollar to below 1.33. The DAX index in ...
GSK tried again with the combination regimens, and two separate Phase 3 trials yielded promising results in 2024. In the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback